Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-016-6 | CAS number: 287-92-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: inhalation
Administrative data
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1992-11-18 to 1992-12-10
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study is classified as reliable without restrictions because it is in compliance with international guidelines for acute inhalation toxicity studies.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 993
- Report date:
- 1993
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Cyclopentane
- EC Number:
- 206-016-6
- EC Name:
- Cyclopentane
- Cas Number:
- 287-92-3
- Molecular formula:
- C5H10
- IUPAC Name:
- cyclopentane
- Details on test material:
- - Name of test material (as cited in study report): cyclopentane
- Physical state: liquid
- Analytical purity: 98.6% a.i.
- Lot/batch No.: Z0002 00132
- Storage condition of test material: 4 degrees celcius in the dark
- Other: clear, colourless liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, UK Limited
- Age at study initiation: male: 6 weeks; female: 8 weeks
- Weight at study initiation: ~200 grams
- Fasting period before study: not reported
- Housing: Stainless steel cages (size 35 cm x 53 cm x 25 cm height) suspended on a movable rack
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18 to 24⁰C
- Humidity (%): 27 to 65%
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light):not reported
IN-LIFE DATES: From: 1992-11-18 To: 1992-12-10
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: Air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: square perspex chambers with pyramidal tops attached to a vapour generator placed in a water bath maintained at 30 degrees celcius
- Exposure chamber volume: 120 Litres
- Method of holding animals in test chamber: wire mesh partitions to hold 10 animals at a time
- Source and rate of air: dried, filtered, oil free air supplied at 25 litres per minute
- Method of conditioning air: not reported
- System of generating particulates/aerosols: atomiser with PTFE tubing fitted with a syringe pump
- Method of particle size determination: not reported
- Treatment of exhaust air: exhaust to atmosphere through a carbon scrubbing system
- Temperature, humidity, pressure in air chamber: 23 to 24 degrees celcius, humidity and pressure not reported
TEST ATMOSPHERE
- Brief description of analytical method used: 5 samples were drawn through a gas absorption trap containing acetone chilled to -70⁰C. Samples were diluted with methanol and then 3µL aliquots of sample solution were inject onto a Gas Chromatography column. Concentration of cylcopentane was calculated using expression:
Cx = (Ax - I)/S where:
Cx = Concentrationof cyclopentane in aliquot (mg/mL)
Ax = Peak area due to cyclopentane
S = Gradient of standard curve
I = Intercept of standard curve
- Samples taken from breathing zone: yes
VEHICLE
- Composition of vehicle (if applicable): air
- Concentration of test material in vehicle (if applicable):25.30 mg/L
- Justification of choice of vehicle: not reported
- Lot/batch no. (if required): not reported
- Purity: not reported
TEST ATMOSPHERE (if not tabulated)
- Particle size distribution:not reported
- MMAD (Mass median aerodynamic diameter) / GSD (Geometric st. dev.): not reported
CLASS METHOD (if applicable)
- Rationale for the selection of the starting concentration: not provided - Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- 25.30 ± 0.76 mg/L
- Duration of exposure:
- ca. 4 h
- Concentrations:
- 25.30 mg/L (26.4 mg/L - nominal concentration)
- No. of animals per sex per dose:
- 5 rats/sex/dose
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical signs monitored at 0.25, 0.50, 1.0 hours and then hourly during exposure and once daily during the 14-day post-expsoure observation period.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, food and water consumption - Statistics:
- Mean and standard deviation (SD) computed for body weight, concentration analysis, food and water consumption, and lung to body weight ratios.
Results and discussion
- Preliminary study:
- The 4-hour inhalation LC50 of cyclopentane is >25.3 mg/L.
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 25.3 mg/L air
- Exp. duration:
- 4 h
- Mortality:
- No deaths were observed.
- Clinical signs:
- other: Hunched posture was observed in all rats (male and female) during hours 1 to 4 of the expsoure period.
- Body weight:
- A few male rats exhibited reduction in bodyweight gain on the day following exposure. Subsequently though, bodyweight gain was similar to that observed in control rats. One male rat also exhibited wet fur around the snout and jaws immediately following exposure period.
- Gross pathology:
- No macroscopic abnormalities were noted in rats exposed to cyclopentane and individual findings such as basophilic cortical tubules in kidneys, macophage aggregates, alveolar hemorrhage and pneumonitis in the lungs were considered spontaneous in origin and not treatment-related.
- Other findings:
- - Organ weights: Lung to body-weight ratios were found to be within normal limits for all male and female rats.
- Other observations: Food consumption was found to be slightly reduced in male rats for a single day while water consumption seemed unaffected following exposure to cyclopentane.
Any other information on results incl. tables
Table 1. Clinical signs during observation period
Group | Signs | Number of animals showing sings | ||||||||||||||
Day of observation period post-exposure | ||||||||||||||||
0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ||
Control Males | Normal behaviour and appearance | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Control Females | Normal behaviour and appearance | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Males (25.3 mg/L) | Normal behaviour and appearance | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Wet fur around snout and jaws | 1 | |||||||||||||||
Females (25.3 mg/L) | Normal behaviour and appearance | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Table 2. Mean body weight during study period.
Group |
Day of Observation and Mean weight in grams |
|||||||||||||||||||
-5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Male Control | 175 | 185 | 194 | 201 | 207 | 213 | 221 | 230 | 239 | 248 | 257 | 264 | 272 | 278 | 283 | 288 | 298 | 303 | 308 | 315 |
Female Control | 189 | 195 | 202 | 207 | 211 | 214 | 216 | 220 | 220 | 225 | 227 | 233 | 231 | 238 | 235 | 238 | 239 | 246 | 248 | 251 |
Male (25.3 mg/L) | 177 | 183 | 194 | 202 | 208 | 217 | 233 | 231 | 238 | 248 | 256 | 265 | 271 | 279 | 284 | 291 | 299 | 305 | 309 | 316 |
Female (25.3 mg/L) | 189 | 191 | 198 | 202 | 201 | 205 | 208 | 214 | 215 | 218 | 223 | 227 | 226 | 228 | 232 | 234 | 236 | 240 | 247 | 248 |
Rats exposed at Day 0. Bodyweight recorded before exposure.
Table 3. Microscopic pathology incidence summary.
Control Males | Males (25.3 mg/L) | Control Females | Females (25.3 mg/L) | |
Animals on study | 5 | 5 | 5 | 5 |
Animals completed | 5 | 5 | 5 | 5 |
Lungs | ||||
Examined | 5 | 5 | 5 | 5 |
No abnormalities detected | 2 | 2 | 3 | 4 |
Penumonitis (Total) | 0 | 0 | 0 | 1 |
Minimal | 0 | 0 | 0 | 1 |
Alveolar collapse | 1 | 0 | 0 | 0 |
Moderate | 1 | 0 | 0 | 0 |
Macrophage aggregates (Total) | 2 | 3 | 0 | 0 |
Minimal | 2 | 2 | 0 | 0 |
Bronchiolar associated lymphoid tissue (Total) | 1 | 0 | 0 | 0 |
Moderate | 1 | 0 | 0 | 0 |
Recent alveolar haemorrhage (Total) | 0 | 1 | 2 | 0 |
Minimal | 0 | 1 | 2 | 0 |
Liver | ||||
Examined | 5 | 5 | 5 | 5 |
No abnormalities detected | 5 | 5 | 5 | 5 |
Kidneys | ||||
Examined | 5 | 5 | 5 | 5 |
No abnormalities detected | 1 | 1 | 4 | 3 |
Basophilic cortical tubules (Total) | 4 | 4 | 1 | 2 |
Minimal | 4 | 4 | 1 | 2 |
Applicant's summary and conclusion
- Interpretation of results:
- other: Not classified
- Remarks:
- Not classified because LC50 is greater than the requirements for a Category 4 vapour toxicant (20 mg/L) Criteria used for interpretation of results: EU
- Conclusions:
- 4-hour acute inhalation toxicity LC50 >25.3 mg/litre
- Executive summary:
In an acute inhalation toxicity study, 5 albino Sprague-Dawley rats/sex were administered 25.30 mg/L (nominal concentration of 26.40 mg/L) of cyclopentane via the inhalation route (whole body exposure) for a period of 4 hours. The rats were observed constantly for signs of reaction during the exposure period and twice daily during the 14-day observation period that followed. Clinical signs were recorded at the end of chamber equilibration period, at 0.25, 0.50, and 1 hours and then at hourly intervals during the exposure period. Clinical signs were recorded once in the morning and then as necessary through the observation period. Bodyweight, food, and water consumption determinations were made daily. At termination, rats were killed and subjected to a detailed macroscopic examination. The liver and kidneys of each rat were evaluated histopathologically under light microscope.
There were no observed mortalities and hunched posture was observed in all rats (male and female) during hours 1 to 4 of the exposure period. A few male rats exhibited reduction in bodyweight gain on the day following exposure. Subsequently though, bodyweight gain was similar to that observed in control rats. Food consumption was found to be slightly reduced in male rats for a single day while water consumption seemed unaffected following exposure to cyclopentane. One male rat also exhibited wet fur around the snout and jaws immediately following the exposure period.
No macroscopic abnormalities were noted in rats exposed to cyclopentane and individual findings such as basophilic cortical tubules in kidneys, macophage aggregates, alveolar hemorrhage and pneumonitis in the lungs were considered spontaneous in origin and not treatment-related. Lung to body-weight ratios were found to be within normal limits for all male and female rats.
Based on the results discussed above, the 4-hour inhalation LC50 for cyclopentane is >25.30 mg/L. Cyclopentane is practically non-toxic in the acute inhalation toxicity test in rats. This study received a Kilmisch score of 1 and is classified as reliable without restrictions because it is in compliance with international guidelines for acute.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.